Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001

Inclusion Criteria: * Male or female, aged between 50 to 75. * Diagnosis of IPF according to 2018 Idiopathic Pulmonary Fibrosis Diagnostic Guidelines. * Participants with 30%\~79% of the predicted value in diffusing capacity for carbon monoxide (DLCO) and more than 50% of the predicted value in forced vital capacity (FVC) in pulmonary function tests within 3 months before screening. * Participants with typical HRCT images of IPF in the past 12 months. * Participants tolerant to bronchofiberscopy. * Participants fully informed with the purpose, method and possible discomfort of the trial, agreeing to participate in the trial and signing the informed consent voluntarily. * Participants with good adherence, willing to take medication and regular follow-up examinations as required by the protocol. * Participants able to understand and cooperate with the completion of pulmonary function tests. Exclusion Criteria: * Participants who cannot tolerate cell therapy. * Pregnant or lactating women. * Participants with syphilis or any of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) positive antibody; of which stable HBV carriers after drug treatment and cured hepatitis C patients can be enrolled. * Participants with malignant tumors or a history of malignant tumors. * Participants with a history of long-term use of drugs known to cause pulmonary fibrosis, such as amiodarone before screening. * Participants with lung infections or other infections, including bacterial and viral infections, with requirement of intravenous medications before cell transplantation. * Participants with a history of invasive or noninvasive mechanical ventilation within 4 weeks. * Participants with any of the following lung diseases: asthma, active tuberculosis, pulmonary embolism, pneumothorax, pulmonary hypertension, pneumoconiosis, etc.; lung cancer, bronchiolitis obliterans or other active lung disease; pneumonia currently or in the past 4 weeks; pneumonectomy previously. * Requirement of oxygen therapy for more than 15 hours per day. * Suffering from serious diseases of other system. * leukopenia or agranulocytosis of any cause; blood creatinine \> 2.5 times the upper limit of normal; alanine transaminase (ALT) and aspartate transaminase (AST) \> 2.5 times the upper limit of normal in the laboratory tests. * Participants with a history of mental illness, suicide risk, epilepsy or other central nervous system disorders. * Severe arrhythmias (such as ventricular tachycardia, frequent supraventricular tachycardia, atrial fibrillation, atrial flutter, etc.) or atrioventricular block of degree II or above, shown by 12-lead Electrocardiogram (ECG). * Participants with a history of abusing alcohol or illicit drug. * Participants allergic to cattle products. * Participants in other clinical trials in the past 3 months. * Participants with poor compliance and difficult to complete the trial. * Investigators, employees of research centers or family members of them (none of whom are suitable to participate in the trial to ensure the objectivity of the research); * Participants with a history of hospitalization owing to acute exacerbation of IPF or other respiratory diseases three or more times within the past year. * Participants who is taking or is goning to take nintedanib within a month. * Participants with other acquired or congenital immunodeficiency disorders, or with a history of organ transplantation or cell transplantation therapy. * Participants whose expected survival may be less than one year judged by the investigator. * Male participants of childbearing potential and female participants within childbearing age were reluctant to use effective contraception from the time of signing the informed consent to 6 months after cell therapy. * Participants assessed to be inappropriate in this clinical trial by investigator.